Literature DB >> 7909617

Primary biliary cirrhosis: contribution of HLA class II allele DR8.

W L Gregory1, W Mehal, A N Dunn, G Cavanagh, R Chapman, K A Fleming, A K Daly, J R Idle, O F James, M F Bassendine.   

Abstract

Primary biliary cirrhosis is a chronic cholestatic disease of unknown aetiology which predominantly affects middle-aged women. It is thought to be autoimmune in nature, but unlike many autoimmune diseases no clear HLA association has been described. Several studies have suggested conflicting associations with HLA class II, although a DR8 association is most frequently described. To test the hypothesis that primary biliary cirrhosis is associated with a certain HLA class II locus we genotyped 130 patients with the disease from the north-east region of England and 363 local healthy controls. HLA-DRB1 and confirmatory DQA and DQB genotypes were determined by TaqI restriction fragment DNA length polymorphism analysis. In addition, a polymerase chain reaction technique (double ARMS) was used to investigate the DRB3 locus (DR52) in 98 primary biliary cirrhosis patients and 107 local controls. We found an increased frequency of HLA-DR8 (18.5% vs 9.2%, p < 0.005, relative risk of 2.0 [1.3-3.1]) in the primary biliary cirrhosis group. HLA-DR8-positive primary biliary cirrhosis patients had a higher serum bilirubin level (p = 0.03) than DR8-negative patients. There was no difference in the DR52 frequencies and no association with markers of disease severity. These results support earlier serological findings, although the association between primary biliary cirrhosis and DR8 is weaker than previously described. In addition, DR8-positivity may identify a clinical subgroup with a worse prognosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7909617

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  8 in total

Review 1.  Genetics and genomics of primary biliary cirrhosis.

Authors:  Brian D Juran; Konstantinos N Lazaridis
Journal:  Clin Liver Dis       Date:  2008-05       Impact factor: 6.126

2.  Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant.

Authors:  Jennifer E Guy; Peiqing Qian; Jeffrey A Lowell; Marion G Peters
Journal:  Liver Transpl       Date:  2005-10       Impact factor: 5.799

3.  T cell responses to the putative dominant autoepitope in primary biliary cirrhosis (PBC).

Authors:  J M Palmer; A G Diamond; S J Yeaman; M F Bassendine; D E Jones
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

4.  HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility.

Authors:  P Donaldson; K Agarwal; A Craggs; W Craig; O James; D Jones
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

5.  Familial clustering and genetic background of primary biliary cirrhosis in Japan.

Authors:  Masatoshi Yanagisawa; Hitoshi Takagi; Hitomi Takahashi; Masahiro Uehara; Toshiyuki Otsuka; Kazuhisa Yuasa; Kenichi Hosonuma; Masatomo Mori
Journal:  Dig Dis Sci       Date:  2009-12-11       Impact factor: 3.199

6.  The role of macrophage migration inhibitory factor in autoimmune liver disease.

Authors:  David N Assis; Lin Leng; Xin Du; Clarence K Zhang; Gerrit Grieb; Melanie Merk; Alvaro Baeza Garcia; Catherine McCrann; Julius Chapiro; Andreas Meinhardt; Yuka Mizue; David J Nikolic-Paterson; Jürgen Bernhagen; Marshall M Kaplan; Hongyu Zhao; James L Boyer; Richard Bucala
Journal:  Hepatology       Date:  2013-12-20       Impact factor: 17.425

7.  First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer.

Authors:  Hiroyasu Oda; Mikiya Ishihara; Yoshihiro Miyahara; Junko Nakamura; Yuji Kozuka; Motoh Iwasa; Akira Tsunoda; Yoshiki Yamashita; Kanako Saito; Toshiro Mizuno; Hiroshi Shiku; Naoyuki Katayama
Journal:  Case Rep Oncol       Date:  2019-02-08

Review 8.  Association of human leukocyte antigen class II with susceptibility to primary biliary cirrhosis: a systematic review and meta-analysis.

Authors:  Baodong Qin; Jiaqi Wang; Jia Chen; Yan Liang; Zaixing Yang; Renqian Zhong
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.